DrugCite
Search

CGS

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Cgs Adverse Events Reported to the FDA Over Time

How are Cgs adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Cgs, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Cgs is flagged as the suspect drug causing the adverse event.

Most Common Cgs Adverse Events Reported to the FDA

What are the most common Cgs adverse events reported to the FDA?

Fall
51 (1.89%)
Arthralgia
37 (1.37%)
Dyspnoea
36 (1.34%)
Atrial Fibrillation
30 (1.11%)
Fatigue
29 (1.08%)
Malignant Neoplasm Progression
27 (1%)
Osteonecrosis
27 (1%)
Hot Flush
26 (.97%)
Death
25 (.93%)
General Physical Health Deteriorati...
25 (.93%)
Pain
25 (.93%)
Show More Show More
Cardiac Failure
23 (.85%)
Uterine Polyp
21 (.78%)
Dizziness
20 (.74%)
Tooth Extraction
19 (.71%)
Nausea
18 (.67%)
Osteosynthesis
18 (.67%)
Pain In Jaw
18 (.67%)
Metastases To Liver
17 (.63%)
Oedema Peripheral
17 (.63%)
Chest Pain
16 (.59%)
Asthenia
15 (.56%)
Bone Pain
15 (.56%)
Surgery
15 (.56%)
Tachycardia
15 (.56%)
Angina Pectoris
14 (.52%)
Pneumonia
14 (.52%)
Polyneuropathy
14 (.52%)
Renal Failure
14 (.52%)
Tooth Abscess
14 (.52%)
Dyspnoea Exertional
13 (.48%)
Femur Fracture
13 (.48%)
Hypertension
13 (.48%)
Hysterectomy
13 (.48%)
Insomnia
13 (.48%)
Osteoporosis
13 (.48%)
Pain In Extremity
13 (.48%)
Swelling
13 (.48%)
Syncope
13 (.48%)
Uterine Dilation And Curettage
13 (.48%)
Chest Discomfort
12 (.45%)
Endometrial Hyperplasia
12 (.45%)
Endometrial Hypertrophy
12 (.45%)
Myalgia
12 (.45%)
Sleep Disorder
12 (.45%)
Anaemia
11 (.41%)
Back Pain
11 (.41%)
Concomitant Disease Progression
11 (.41%)
Headache
11 (.41%)
Hysteroscopy
11 (.41%)
Mitral Valve Incompetence
11 (.41%)
Osteoarthritis
11 (.41%)
Pulmonary Embolism
11 (.41%)
Pulmonary Oedema
11 (.41%)
Pyrexia
11 (.41%)
Cardiac Disorder
10 (.37%)
Cardiomegaly
10 (.37%)
Cholelithiasis
10 (.37%)
Lymphadenectomy
10 (.37%)
Neuropathy Peripheral
10 (.37%)
Radius Fracture
10 (.37%)
Restrictive Cardiomyopathy
10 (.37%)
Visual Impairment
10 (.37%)
Atrial Tachycardia
9 (.33%)
Cardiotoxicity
9 (.33%)
Cataract
9 (.33%)
Coronary Artery Disease
9 (.33%)
Erythema
9 (.33%)
Gait Disturbance
9 (.33%)
Stomatitis
9 (.33%)
Weight Increased
9 (.33%)
Cardiac Pacemaker Insertion
8 (.3%)
Carpal Tunnel Syndrome
8 (.3%)
Confusional State
8 (.3%)
Drug Ineffective
8 (.3%)
Epistaxis
8 (.3%)
External Fixation Of Fracture
8 (.3%)
Gingival Bleeding
8 (.3%)
Hypercholesterolaemia
8 (.3%)
Hypokinesia
8 (.3%)
Metastases To Bone
8 (.3%)
Neoplasm Malignant
8 (.3%)
Osteomyelitis
8 (.3%)
Soft Tissue Infection
8 (.3%)
Vaginal Haemorrhage
8 (.3%)
Abdominal Pain Upper
7 (.26%)
Cardiac Murmur
7 (.26%)
Cholecystectomy
7 (.26%)
Constipation
7 (.26%)
Ejection Fraction Decreased
7 (.26%)
Endocervical Curettage
7 (.26%)
Gingival Infection
7 (.26%)
Hyperhidrosis
7 (.26%)
Hypophagia
7 (.26%)
Listless
7 (.26%)
Palpitations
7 (.26%)
Pancytopenia
7 (.26%)
Panic Attack
7 (.26%)
Rales
7 (.26%)
Renal Impairment
7 (.26%)
Sinus Tachycardia
7 (.26%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Cgs, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Cgs is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Cgs

What are the most common Cgs adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Cgs, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Cgs is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Cgs According to Those Reporting Adverse Events

Why are people taking Cgs, according to those reporting adverse events to the FDA?

Breast Cancer
641
Bone Density Decreased
7
Resorption Bone Increased
7
Uterine Leiomyosarcoma
3
Antioestrogen Therapy
2
Adjuvant Therapy
2
Show More Show More
Endometrial Cancer
1
Breast Cancer Metastatic
1
Metastases To Bone
1

Cgs Case Reports

What Cgs safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Cgs. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Cgs.